Andrew C Don-Wauchope1, Robert S McKelvie2. 1. Department of Pathology and Molecular Medicine, McMaster University and Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada. Electronic address: donwauc@mcmaster.ca. 2. Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: The B-type natriuretic peptides are now available on many automated clinical analysers. Clinical practice guidelines for heart failure include recommendations for where the B-type natriuretic peptides are possibly useful for clinical practice. A number of systematic reviews considering B-type natriuretic peptides in relation to heart failure patients have been published. METHODS: This review will consider the evidence presented in the systematic reviews and how this can be applied to clinical practice. RESULTS: Twenty-six systematic reviews are summarised in tables considering applications to diagnostic, prognostic and guiding therapy. Important clinical considerations for these applications are discussed to facilitate appropriate implementation in the clinical laboratory. CONCLUSION: Most clinical laboratories should be considering the appropriate implementation of the B-type natriuretic peptide as a diagnostic test to assist in ruling out heart failure. In the application of prognosis and guiding therapy a number of questions remain to be answered.
BACKGROUND: The B-type natriuretic peptides are now available on many automated clinical analysers. Clinical practice guidelines for heart failure include recommendations for where the B-type natriuretic peptides are possibly useful for clinical practice. A number of systematic reviews considering B-type natriuretic peptides in relation to heart failurepatients have been published. METHODS: This review will consider the evidence presented in the systematic reviews and how this can be applied to clinical practice. RESULTS: Twenty-six systematic reviews are summarised in tables considering applications to diagnostic, prognostic and guiding therapy. Important clinical considerations for these applications are discussed to facilitate appropriate implementation in the clinical laboratory. CONCLUSION: Most clinical laboratories should be considering the appropriate implementation of the B-type natriuretic peptide as a diagnostic test to assist in ruling out heart failure. In the application of prognosis and guiding therapy a number of questions remain to be answered.
Authors: Nicole E Pollok; Charlie Rabin; Charuksha T Walgama; Leilani Smith; Ian Richards; Richard M Crooks Journal: ACS Sens Date: 2020-03-10 Impact factor: 7.711
Authors: Daniel Staub; Sasan Partovi; Thomas Zeller; Tobias Breidthardt; Max Kaech; Jasper Boeddinghaus; Christian Puelacher; Thomas Nestelberger; Markus Aschwanden; Christian Mueller Journal: Cardiovasc Diagn Ther Date: 2016-06